Not finding it? Sign in to also search OpenAlex live.
-
Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial2022 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology Extracellular vesicles in disease Open access
Timothy Wai Ho Shuen, Marianna Alunni‐Fabbroni, Elif Öcal, Peter Malfertheiner, Moritz Wildgruber, Regina Schinner, +8 more
40citations -
Data from Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial2023 other Biochemistry, Genetics and Molecular Biology Extracellular vesicles in disease Open access
Timothy Wai Ho Shuen, Marianna Alunni‐Fabbroni, Elif Öcal, Peter Malfertheiner, Moritz Wildgruber, Regina Schinner, +8 more
0citations -
Data from Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial2023 other Biochemistry, Genetics and Molecular Biology Extracellular vesicles in disease Open access
Timothy Wai Ho Shuen, Marianna Alunni‐Fabbroni, Elif Öcal, Peter Malfertheiner, Moritz Wildgruber, Regina Schinner, +8 more
0citations -
Abstract 5876: Sorafenib and Lenvatinib induce vascular responses in patient derived HCC on-Chip models2023 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Angiogenesis and VEGF in Cancer
Orsola Mocellin, Abbie Robinson, Aleksandra Olczyk, Stéphane Treillard, Thomas Olivier, Chee Ping Ng, +9 more
1citations -
Peer Review Report For: Therapeutic Drug Monitoring of Sorafenib and Lenvatinib in Hepatocellular Carcinoma Patients – A Key to Personalised Pharmacotherapy [version 2; peer review: 3 approved with reservations]
Shine Sadasivan, T P Aneesh, Teun van Gelder, Shiny Thomas, C T Aravindkumar, Niveditha Kartha, +1 more
0citations -
Peer Review Report For: Therapeutic Drug Monitoring of Sorafenib and Lenvatinib in Hepatocellular Carcinoma Patients – A Key to Personalised Pharmacotherapy [version 2; peer review: 2 approved with reservations]
Shine Sadasivan, T P Aneesh, Teun van Gelder, Shiny Thomas, C T Aravindkumar, Niveditha Kartha, +1 more
0citations -
The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro2022 Journal of Cellular and Molecular Medicine article Medicine Glioma Diagnosis and Treatment Open access
Leonie F. Schoen, Rogerio Bastos Craveiro, Torsten Pietsch, Thomas Moritz, Anja Troeger, Silvia Jordans, +1 more
9citations -
191P Evaluating sorafenib as second-line treatment for advanced hepatocellular carcinoma: SORA-2, an European retrospective multicenter study2024 Annals of Oncology article Medicine Hepatocellular Carcinoma Treatment and Prognosis Open access
Christian Möhring, Moritz Berger, Farsaneh Sadeghlar, M-L. Berres, I-P. Radu, Christoph Roderburg, +11 more
1citations -
Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)2023 Zeitschrift für Gastroenterologie article Medicine Hepatocellular Carcinoma Treatment and Prognosis
Marie‐Luise Berres, Stephen Lam Chan, Masatoshi Kudo, Bruno Sangro, Robin Kate Kelley, Junji Furuse, +15 more
0citations -
Experimental mouse model of hepatocellular carcinoma with and without parenchymal liver damage for rapid screening of antitumor drugs2023 Zeitschrift für Gastroenterologie article Medicine Hepatocellular Carcinoma Treatment and Prognosis
Paul M. Schneider, Karina Benderski, Alexandros Marios Sofias, Twan Lammers, Barbara Schrörs, Mustafa Diken, +2 more
0citations -
Modeling Hepatocellular Carcinoma and its microenvironment on a chip Hepatocellular carcinoma PDChip2025 bioRxiv (Cold Spring Harbor Laboratory) preprint Engineering 3D Printing in Biomedical Research Open access
Orsola Mocellin, Stéphane Treillard, Abbie Robinson, Aleksandra Olczyk, Thomas Olivier, Chee Ping Ng, +9 more
1citations -
Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).2023 Journal of Clinical Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
George K.K. Lau, Bruno Sangro, Oxana Crysler, Wattana Sukeepaisarnjaroen, Oleg Nikolaevich Lipatov, Manabu Morimoto, +12 more
8citations -
Cancer-Associated Fibroblast-Centric Risk Model Predicts Immunotherapy Resistance in Pancreatic Cancer and Reveals PLOD2 as a Key Stromal Therapeutic Target2025 Frontiers in Bioscience-Landmark article Medicine Pancreatic and Hepatic Oncology Research Open access
Pengwei Cao, Feng Cao, Zhihua null Shui, X. Zhang, Mengjie Lv, Hu Xu, +5 more
2citations